Maravai Lifesciences Holdings (MRVI) AI Stock Analysis

• Market Cap: $695.22M
• Dividend Yield: N/A
• Average Volume (3M): 1.83M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.62
• Revenue Growth: -11.76%
• EPS Growth: -15.82%
• Country: US
• Employees: 570
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -0.08
• Shares Outstanding: 143,975,430
• 10 Day Avg. Volume: 1,633,524
• 30 Day Avg. Volume: 1,827,133
• PEG Ratio: 0.20
• Price to Book (P/B): 1.27
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -58.72
• Enterprise Value/Market Cap: 1.60
• Enterprise Value/Revenue: 1.05
• Enterprise Value/Gross Profit: 12.35
• Enterprise Value/Ebitda: 1.26
• 1Y Price Target: $4.60
• Price Target Upside: 68.50% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 7

• Rating: 53 Neutral
• Price Target: $2.50 ▼(-8.42%Downside)

Maravai Lifesciences Holdings faces notable financial hurdles, with profitability and cash flow challenges being the most critical factors weighing on the stock score. Technical analysis shows some short-term positive momentum but is overshadowed by longer-term bearish trends. Recent earnings guidance was positive, but ongoing profitability issues and geopolitical risks complicate the outlook. Valuation remains a concern due to negative earnings and the absence of dividends.

Positive Factors

Executive Experience

Rajesh 'Raj' Asarpota brings nearly 30 years of executive leadership experience across public and private life sciences and medical device industries, including a decade as CFO of public and private companies.

Leadership and Management

Raj Asarpota's familiarity with the new CEO and major shareholder GTCR is expected to be beneficial as the company develops a new strategic vision.

Potential Acquisition

There is speculation about a potential acquisition of Maravai, which could lead to increased investor interest and potential premium offers.

Negative Factors

Financial Guidance

The company has not updated or reaffirmed its financial guidance, indicating potential uncertainty in its financial outlook.

Operational Transitions

Maravai is experiencing significant operational transitions as it works to overcome the impact of COVID revenues rolling off its P&L statement, presenting challenges to its non-COVID business growth.

Revenue Challenges

Maravai's non-COVID business has declined year-over-year for nine consecutive quarters, indicating persistent challenges in its key end-markets.

Maravai Lifesciences Holdings Business Overview & Revenue Model

Company Description

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was incorporated in 2020 and is headquartered in San Diego, California.

How the Company Makes Money

Maravai Lifesciences Holdings makes money primarily through the sale of its life science products and services. The company generates revenue by providing high-quality reagents and services that are critical in the development and manufacturing processes of biopharmaceuticals and diagnostics. Key revenue streams include nucleic acid products, which are essential for mRNA-based therapies and vaccines, biologics safety testing for ensuring the safety and efficacy of drugs, and protein detection products used in research and development. Significant partnerships with biotech firms and research institutions also contribute to its earnings by expanding its market reach and customer base.

Maravai Lifesciences Holdings Financial Statement Overview

Summary

Maravai Lifesciences Holdings faces significant financial challenges. Declining revenue and profitability have led to negative margins and cash flow issues. Despite a low leverage position, the reduction in shareholder equity and assets signals potential risks. Improvement in revenue and cost management is crucial for financial stability and growth.

Income Statement

The income statement reveals significant challenges, with the company experiencing negative EBIT and net income in the TTM period. Revenue has declined from the previous year, highlighting a concerning trend. Margins, including gross profit and EBITDA, have deteriorated, indicating profitability issues.

Balance Sheet

The balance sheet shows a moderate financial position. The debt-to-equity ratio is low due to reduced total debt, suggesting manageable leverage. However, the equity ratio has decreased, reflecting reduced shareholder equity. The decline in total assets and equity over time is a concern.

Cash Flow

Cash flow analysis indicates pressure, with a negative free cash flow in the TTM period. The operating cash flow to net income ratio is positive, but both operating and free cash flows have declined, reflecting cash management challenges. The company needs to enhance cash generation strategies.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	241.86M	259.19M	288.94M	883.00M	799.24M	284.10M
Gross Profit	90.19M	108.31M	140.20M	714.04M	658.68M	204.45M
EBITDA	-208.29M	-156.92M	712.41M	609.99M	585.78M	138.27M
Net Income	-162.71M	-144.85M	-119.03M	490.66M	469.25M	76.89M
Balance Sheet
Total Assets	959.75M	1.01B	1.49B	2.28B	1.92B	1.27B
Cash, Cash Equivalents and Short-Term Investments	285.05M	322.40M	574.96M	632.14M	551.27M	236.18M
Total Debt	37.16M	376.69M	610.97M	585.26M	534.31M	590.78M
Total Liabilities	429.48M	431.04M	697.57M	1.38B	1.37B	1.12B
Stockholders Equity	300.61M	325.29M	416.75M	545.22M	315.50M	88.51M
Cash Flow
Free Cash Flow	-23.19M	-22.19M	60.67M	518.89M	353.72M	126.78M
Operating Cash Flow	6.54M	7.46M	126.22M	535.98M	368.57M	152.19M
Investing Cash Flow	-43.20M	-24.32M	-122.31M	-267.61M	105.66M	6.07M
Financing Cash Flow	-238.81M	-234.47M	-61.09M	-187.50M	-159.05M	53.21M

Maravai Lifesciences Holdings Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.73
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MRVI, the sentiment is Positive. The current price of 2.73 is above the 20-day moving average (MA) of 2.43, above the 50-day MA of 2.27, and below the 200-day MA of 4.23, indicating a neutral trend. The MACD of 0.15 indicates Negative momentum. The RSI at 59.28 is Neutral, neither overbought nor oversold. The STOCH value of 72.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MRVI.

Maravai Lifesciences Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PHAR	66 Neutral	$691.35M	―	-6.33%	―	23.92%	-27.69%
Sector *	64 Neutral	¥343.53B	10.93	-2.99%	2.55%	11.77%	-9.96%
MRVI	53 Neutral	$695.22M	―	-45.75%	―	-11.76%	-15.82%
BCAX	48 Neutral	$529.55M	―	34.94%	―	―	―
LENZ	46 Neutral	$976.39M	―	-24.47%	―	―	68.93%
IMNM	46 Neutral	$751.79M	―	-69.21%	―	-13.76%	57.73%
COGT	37 Underperform	$1.80B	―	-84.04%	―	―	-2.53%

Maravai Lifesciences Holdings Corporate Events

Maravai Lifesciences Appoints New CFO Rajesh Asarpota

On June 22, 2025, Maravai LifeSciences announced the appointment of Rajesh Asarpota as Chief Financial Officer, effective June 30, 2025, succeeding Kevin Herde. Mr. Asarpota, with extensive experience in finance and strategic growth in the life sciences and medical device sectors, will lead Maravai’s financial and strategic initiatives, supporting its focus on nucleic acid technologies and bioprocess impurity analytics. This transition aims to strengthen Maravai’s leadership team and drive long-term value creation for stakeholders.

The most recent analyst rating on (MRVI) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Maravai Lifesciences Holdings stock, see the MRVI Stock Forecast page.

Maravai Lifesciences Appoints Bernd Brust as New CEO

On June 8, 2025, Maravai LifeSciences Holdings appointed Bernd Brust as the new CEO and member of the Board, succeeding William E. Martin, III. This leadership transition aims to enhance innovation and financial performance, with Brust bringing over 30 years of experience in the life sciences industry. The company is poised for long-term success with a strong financial foundation and a commitment to expanding its market leadership in mRNA and bioprocess impurity detection. Maravai plans to continue delivering innovative solutions to researchers and biotech innovators globally.

The most recent analyst rating on (MRVI) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Maravai Lifesciences Holdings stock, see the MRVI Stock Forecast page.

Maravai Lifesciences Holds Annual Shareholders Meeting

On May 22, 2025, Maravai LifeSciences Holdings, Inc. conducted its Annual Meeting of Shareholders. During the meeting, shareholders elected directors for three-year terms, ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for 2025, and approved the compensation of the company’s named executive officers on a non-binding advisory basis.

The most recent analyst rating on (MRVI) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Maravai Lifesciences Holdings stock, see the MRVI Stock Forecast page.